Short-term enzalutamide treatment for the potential remission of active surveillance or intermediate-risk prostate cancer: a case study, review, and the need for a clinical trial
Mark A Moyad,1 Mark C Scholz21Department of Urology, Jenkins/Pokempner Preventive and Complementary Medicine, University of Michigan Hospitals and Health Centers, Ann Arbor, MI, USA; 2Prostate Oncology Specialists, Marina del Rey, CA, USAAbstract: Active surveillance (AS) is a widely recognized and utilized option by which prostate cancer patients